Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist
作者:Changsheng Zheng、Ganfeng Cao、Michael Xia、Hao Feng、Joseph Glenn、Rajan Anand、Ke Zhang、Taisheng Huang、Anlai Wang、Ling Kong、Mei Li、Laurine Galya、Robert O. Hughes、Rajesh Devraj、Phillip A. Morton、D. Joseph Rogier、Maryanne Covington、Fred Baribaud、Niu Shin、Peggy Scherle、Sharon Diamond、Swamy Yeleswaram、Kris Vaddi、Robert Newton、Greg Hollis、Steven Friedman、Brian Metcalf、Chu-Biao Xue
DOI:10.1016/j.bmcl.2011.01.015
日期:2011.3
We report the discovery of a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist (3S,4S)-N-[(1R,3S)-3-isopropyl-3-(4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)cyclopentyl]-3-methoxytetrahydro-2H-pyran-4-amine (19). After evaluation in 28-day toxicology studies, compound 19 (INCB10820/PF-4178903) was selected as a clinical candidate. (C) 2011 Elsevier Ltd. All rights reserved.